BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Buijs M, Reyes DK, Pawlik TM, Blackford AL, Salem R, Messersmith WA, Weekes CD, Mulcahy M, Kamel IR, Geschwind JF. Phase 2 trial of concurrent bevacizumab and transhepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. Cancer. 2013;119:1042-1049. [PMID: 23132335 DOI: 10.1002/cncr.27859] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Taussig MD, Irene Koran ME, Mouli SK, Ahmad A, Geevarghese S, Baker JC, Lipnik AJ, Banovac F, Brown DB. Neutrophil to lymphocyte ratio predicts disease progression following intra-arterial therapy of hepatocellular carcinoma. HPB 2017;19:458-64. [DOI: 10.1016/j.hpb.2017.01.013] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
2 Page AJ, Cosgrove DC, Philosophe B, Pawlik TM. Hepatocellular Carcinoma. Surgical Oncology Clinics of North America 2014;23:289-311. [DOI: 10.1016/j.soc.2013.10.006] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 5.0] [Reference Citation Analysis]
3 Vacchelli E, Aranda F, Eggermont A, Galon J, Sautès-Fridman C, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy. Oncoimmunology 2014;3:e27048. [PMID: 24605265 DOI: 10.4161/onci.27048] [Cited by in Crossref: 59] [Cited by in F6Publishing: 58] [Article Influence: 59.0] [Reference Citation Analysis]
4 Fako V, Wang XW. The status of transarterial chemoembolization treatment in the era of precision oncology. Hepat Oncol 2017;4:55-63. [PMID: 28989699 DOI: 10.2217/hep-2017-0009] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
5 Liamis G, Filippatos TD, Elisaf MS. Electrolyte disorders associated with the use of anticancer drugs. Eur J Pharmacol. 2016;777:78-87. [PMID: 26939882 DOI: 10.1016/j.ejphar.2016.02.064] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 5.7] [Reference Citation Analysis]
6 Li G, Liang Y, Sun C, Peng X, Hao N, Liu M, Gao W, Wu H, He B. Effective combination therapy of percutaneous ethanol injection and chemotherapy based on injectable low molecular weight gels. Artif Cells Nanomed Biotechnol 2018;46:683-93. [PMID: 29741394 DOI: 10.1080/21691401.2018.1468766] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
7 McNamara MG, Knox JJ. Systemic therapy for hepatocellular carcinoma. Hepat Oncol 2014;1:23-38. [PMID: 30190939 DOI: 10.2217/hep.13.10] [Reference Citation Analysis]
8 Heindryckx F, Gerwins P. Targeting the tumor stroma in hepatocellular carcinoma. World J Hepatol 2015; 7(2): 165-176 [PMID: 25729472 DOI: 10.4254/wjh.v7.i2.165] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 5.1] [Reference Citation Analysis]
9 Hyder O, Marsh JW, Salem R, Petre EN, Kalva S, Liapi E, Cosgrove D, Neal D, Kamel I, Zhu AX, Sofocleous CT, Geschwind JF, Pawlik TM. Intra-arterial therapy for advanced intrahepatic cholangiocarcinoma: a multi-institutional analysis. Ann Surg Oncol. 2013;20:3779-3786. [PMID: 23846786 DOI: 10.1245/s10434-013-3127-y] [Cited by in Crossref: 74] [Cited by in F6Publishing: 118] [Article Influence: 8.2] [Reference Citation Analysis]
10 Smolka S, Chapiro J, Manzano W, Treilhard J, Reiner E, Deng Y, Zhao Y, Hamm B, Duncan JS, Gebauer B, Lin M, Geschwind JF. The impact of antiangiogenic therapy combined with Transarterial Chemoembolization on enhancement based quantitative tumor response assessment in patients with hepatocellular carcinoma. Clin Imaging 2017;46:1-7. [PMID: 28668723 DOI: 10.1016/j.clinimag.2017.05.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
11 Lin HS, Huang YL, Wang YS, Hsiao E, Hsu TA, Shiao HY, Jiaang WT, Sampurna BP, Lin KH, Wu MS, Lai GM, Yuh CH. Identification of Novel Anti-Liver Cancer Small Molecules with Better Therapeutic Index than Sorafenib via Zebrafish Drug Screening Platform. Cancers (Basel) 2019;11:E739. [PMID: 31141996 DOI: 10.3390/cancers11060739] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 8.0] [Reference Citation Analysis]
12 Haskal ZJ. Editor's suggested readings in interventional oncology. J Vasc Interv Radiol 2013;24:1165-6. [PMID: 23885914 DOI: 10.1016/j.jvir.2013.05.068] [Reference Citation Analysis]
13 Corona-Villalobos CP, Zhang Y, Zhang WD, Kamel IR. Magnetic resonance imaging of the liver after loco-regional and systemic therapy. Magn Reson Imaging Clin N Am 2014;22:353-72. [PMID: 25086934 DOI: 10.1016/j.mric.2014.04.008] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
14 Welker MW, Trojan J. Antiangiogenic treatment in hepatocellular carcinoma: the balance of efficacy and safety. Cancer Manag Res 2013;5:337-47. [PMID: 24204170 DOI: 10.2147/CMAR.S35029] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
15 Pinter M, Ulbrich G, Sieghart W, Kölblinger C, Reiberger T, Li S, Ferlitsch A, Müller C, Lammer J, Peck-Radosavljevic M. Hepatocellular Carcinoma: A Phase II Randomized Controlled Double-Blind Trial of Transarterial Chemoembolization in Combination with Biweekly Intravenous Administration of Bevacizumab or a Placebo. Radiology 2015;277:903-12. [PMID: 26131911 DOI: 10.1148/radiol.2015142140] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 4.9] [Reference Citation Analysis]
16 Khaled NB, Seidensticker M, Ricke J, Mayerle J, Oehrle B, Rössler D, Teupser D, Ehmer U, Bitzer M, Waldschmidt D, Fuchs M, Reuken PA, Lange CM, Wege H, Kandulski A, Dechêne A, Venerito M, Berres ML, Luedde T, Kubisch I, Reiter FP, De Toni EN. Atezolizumab and bevacizumab with transarterial chemoembolization in hepatocellular carcinoma: the DEMAND trial protocol. Future Oncol 2022. [PMID: 35081747 DOI: 10.2217/fon-2021-1261] [Reference Citation Analysis]
17 Fiorentini G, Sarti D, Nardella M, Inchingolo R, Nestola M, Rebonato A, Guadagni S. Chemoembolization Alone or Associated With Bevacizumab for Therapy of Colorectal Cancer Metastases: Preliminary Results of a Randomized Study. In Vivo 2020;34:683-6. [PMID: 32111770 DOI: 10.21873/invivo.11824] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
18 Sakr OS, Berndt S, Carpentier G, Cuendet M, Jordan O, Borchard G. Arming embolic beads with anti-VEGF antibodies and controlling their release using LbL technology. J Control Release 2016;224:199-207. [PMID: 26780173 DOI: 10.1016/j.jconrel.2016.01.010] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
19 Berretta M, Rinaldi L, Di Benedetto F, Lleshi A, De Re V, Facchini G, De Paoli P, Di Francia R. Angiogenesis Inhibitors for the Treatment of Hepatocellular Carcinoma. Front Pharmacol 2016;7:428. [PMID: 27881963 DOI: 10.3389/fphar.2016.00428] [Cited by in Crossref: 32] [Cited by in F6Publishing: 36] [Article Influence: 5.3] [Reference Citation Analysis]
20 Xu L, Liang Y, Sun C, Hao N, Yan J, Gao W, He B. Substitution of Percutaneous Ethanol Injection with a Low Molecular Weight Peptide Gel Mimicking Chemoembolization for Cancer Therapy. Nanotheranostics 2017;1:313-25. [PMID: 29071195 DOI: 10.7150/ntno.20468] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
21 Shen YC, Lin ZZ, Hsu CH, Hsu C, Shao YY, Cheng AL. Clinical trials in hepatocellular carcinoma: an update. Liver Cancer 2013;2:345-64. [PMID: 24400222 DOI: 10.1159/000343850] [Cited by in Crossref: 43] [Cited by in F6Publishing: 47] [Article Influence: 5.4] [Reference Citation Analysis]